Drug used to treat heart failure led to dozens of deaths
New drug approved to treat chronic heart failure.The article discusses research being done on the use of ivabradine in treating chronic heart failure, which references the article "FDA approves Corlanor (ivabradine) to reduce the risk of hospitalization for worsening heart failure in patients with ...
Heart failure is a global health problem commonly complicated by sleep apnea, a co-morbidity that further reduces a person’s lifespan. A promising new drug has been developed that could treat heart failure and sleep apnea by targeting the nervous activity that drives bot...
5.Clinical Observation on the Effect of Jiuxin Soap on the Patients with Chronic Heart Failure救心汤治疗慢性心力衰竭的临床研究 6.Clinical Research on Chronic Heart Failure Treated with WenXin Decoction温心汤治疗慢性心力衰竭的临床研究 7.Efficacy of Huoxueyixin decoction to treat chronic congestive hea...
Heart failure is a variety of cardiovascular diseases in the final stages of development,is the most organic heart disease progression in the final outcome and is the most important cause of death.In order to treat heart failure more effectively,reversal of cardiac remodeling,improve the survival ...
A potential drug to treat heart attacks and to prevent heart failure — for which no cure currently exists — may result from pioneering research by a University of Guelph professor. Professor Tami Martino, Department of Biomedical Sciences, and Ph.D. student Cristine Reitz have discovered...
The incremental use of drug combinations could prevent hospitalizations from heart failure among those who have higher ejection farction, a subgroup that struggles with insufficient data on treatments. Researchers suggest that sodium-glucose cotransporter 2 (SGLT2) inhib...
FDA approves Corlanor to treat heart failure FDA has approved ivabradine (Corlanor, Amgen) to reduce hospitalization due to worsening heart failure. Corlanor is an antianginal agent approved for use in patients who have chronic heart failure caused by the lower-left part of the hea... E Basti...
Despite considerable therapeutic advances, treatment of acute decompensated heart failure has not changed much over the past 25 years, as new drugs have failed to reduce morbidity and mortality rates compared to placebo. Furthermore, no treatment strategy has improved clinical outcomes in patients with...
Given the ethical imperative to treat with ACE inhibitors, the angiotensin receptor antagonists have been difficult to study; nevertheless, their value is becoming increasingly clear, particularly for patients intolerant of ACE inhibitors. Trials with several classes of newer agents—cytokine antagonists, ...